Latest news with #ProMedicusLimited
Business Insider
05-07-2025
- Business
- Business Insider
Pro Medicus Limited (PMCUF) Gets a Hold from RBC Capital
In a report released on July 3, Garry Sherriff from RBC Capital maintained a Hold rating on Pro Medicus Limited, with a price target of A$350.00. The company's shares closed last Thursday at $203.50. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Sherriff covers the Technology sector, focusing on stocks such as Xero Limited, Wisetech Global, and Nuix Ltd.. According to TipRanks, Sherriff has an average return of 14.9% and a 66.25% success rate on recommended stocks. In addition to RBC Capital, Pro Medicus Limited also received a Hold from Bell Potter's John Hester in a report issued yesterday. However, on the same day, Morgans maintained a Sell rating on Pro Medicus Limited (Other OTC: PMCUF). Based on Pro Medicus Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $97.19 million and a net profit of $51.75 million. In comparison, last year the company earned a revenue of $74.11 million and had a net profit of $36.25 million
Business Insider
28-06-2025
- Business
- Business Insider
Pro Medicus Limited (PMCUF) Receives a Buy from Goldman Sachs
In a report released yesterday, Kane Hannan from Goldman Sachs maintained a Buy rating on Pro Medicus Limited (PMCUF – Research Report), with a price target of A$310.00. The company's shares closed yesterday at $179.69. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hannan covers the Communication Services sector, focusing on stocks such as REA Group Ltd, Telstra Corporation Limited, and oOh media Ltd. According to TipRanks, Hannan has an average return of 10.4% and a 62.57% success rate on recommended stocks. Currently, the analyst consensus on Pro Medicus Limited is a Moderate Sell with an average price target of $154.07. Based on Pro Medicus Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $97.19 million and a net profit of $51.75 million. In comparison, last year the company earned a revenue of $74.11 million and had a net profit of $36.25 million
Yahoo
14-02-2025
- Business
- Yahoo
Pro Medicus Limited (ASX:PME) Released Earnings Last Week And Analysts Lifted Their Price Target To AU$253
Last week, you might have seen that Pro Medicus Limited (ASX:PME) released its half-yearly result to the market. The early response was not positive, with shares down 3.1% to AU$279 in the past week. Results overall were respectable, with statutory earnings of AU$0.49 per share roughly in line with what the analysts had forecast. Revenues of AU$97m came in 3.9% ahead of analyst predictions. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Pro Medicus after the latest results. Check out our latest analysis for Pro Medicus Following the latest results, Pro Medicus' 13 analysts are now forecasting revenues of AU$215.8m in 2025. This would be a decent 16% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to ascend 17% to AU$1.10. In the lead-up to this report, the analysts had been modelling revenues of AU$214.6m and earnings per share (EPS) of AU$1.07 in 2025. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates. The consensus price target rose 15% to AU$253, suggesting that higher earnings estimates flow through to the stock's valuation as well. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Pro Medicus analyst has a price target of AU$330 per share, while the most pessimistic values it at AU$46.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Pro Medicus' growth to accelerate, with the forecast 35% annualised growth to the end of 2025 ranking favourably alongside historical growth of 26% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Pro Medicus is expected to grow much faster than its industry. The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Pro Medicus' earnings potential next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Pro Medicus analysts - going out to 2027, and you can see them free on our platform here. That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Pro Medicus , and understanding this should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
05-02-2025
- Business
- Yahoo
Despite recent sales, Pro Medicus Limited (ASX:PME) insiders remain the largest stockholders with 49% ownership
Insiders appear to have a vested interest in Pro Medicus' growth, as seen by their sizeable ownership The top 4 shareholders own 51% of the company Insiders have been selling lately If you want to know who really controls Pro Medicus Limited (ASX:PME), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 49% to be precise, is individual insiders. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Insiders are at the top of the company's shareholdings despite selling some shares recently. As a result, they were also the biggest winners as market cap hit AU$30b last week. Let's take a closer look to see what the different types of shareholders can tell us about Pro Medicus. View our latest analysis for Pro Medicus Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Pro Medicus. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Pro Medicus' earnings history below. Of course, the future is what really matters. Pro Medicus is not owned by hedge funds. With a 23% stake, CEO Sam Hupert is the largest shareholder. In comparison, the second and third largest shareholders hold about 23% and 2.8% of the stock. Interestingly, the second-largest shareholder, Anthony Hall is also Top Key Executive, again, pointing towards strong insider ownership amongst the company's top shareholders. To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. It seems insiders own a significant proportion of Pro Medicus Limited. It has a market capitalization of just AU$30b, and insiders have AU$15b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling. The general public-- including retail investors -- own 37% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It's always worth thinking about the different groups who own shares in a company. But to understand Pro Medicus better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Pro Medicus (of which 1 can't be ignored!) you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
